The outcome of acute myeloid leukemia patients with primary refractoriness to conventional chemotherapy is extremely poor. Allogeneic bone marrow transplants with matched sibling or matched unrelated donors provide 10-20% disease-free survival in this setting. We analyzed our transplant experience using readily available partially mismatched related donor (PMRD) in patients with primary induction failure (PIF) AML. Between March 1994 and December 1998, 13 patients with PIF AML were transplanted from 0-3 HLA antigen mismatched donors. All 12 evaluable patients engrafted at a median of day +16. Ten (77%) patients survived at least 100 days after transplant. Acute GVHD (grade II) was observed in one of 12 patients. Chronic GVHD was seen in one of 10 patients surviving beyond day 100. The major cause of failure was relapse of disease in six occurring 3-12 months after PMRD BMT. Three patients are alive without disease 14, 36 and 45 months post BMT with Karnofsky scores of 100%. The actuarial 3-year probabilities of relapse and disease-free survival were 0.54 and 0.19, respectively. We concluded that a PMRD graft is a viable option, comparable to the use of matched related or unrelated donors, in patients with PIF AML in whom time is of the essence. Bone Marrow Transplantation (2000) 27, 507-510.
With the advancement of chemotherapy, 60-80% of patients with newly diagnosed acute myeloid leukemia can reach complete remission with conventional induction therapy. 1 However, only half of those patients will remain in long-term disease-free status despite intensive consolidation chemotherapy. 2 Even with an aggressive salvage regimen, the outcome is poor for these high-risk patients who either never respond to initial induction chemotherapy or who experience recurrence after achieving remission. 3 Allogeneic bone marrow transplantation is the only treatment option available to potentially improve long-term survival in this patient population. An early report 4 of matched sibling donor transplants from the International Bone Marrow Transplant Registry (IBMTR) showed a 3-year probability of leukemia-free survival of 0.21 for patients with AML who never achieved remission prior to transplant. However, the availability of a matched sibling donor is limited by the change of social/family structure and its natural inherent biological patterns, and therefore, an approach using alternative donors has been increasingly explored. The Seattle transplant team reported their experience with unrelated donor transplantation for refractory acute leukemia which showed a 5-year disease-free survival of 0.14. 5 We reviewed our experience in patients with primary induction failure AML who received a partially T celldepleted bone marrow graft from a mismatched family member using a total body radiation-based conditioning regimen and post-transplant cyclosporine (CsA), steroids, and anti-thymocyte globulin (ATG) immunosuppression as GVHD prophylaxis. Our results were comparable with those of previous reports. Partially mismatched bone marrow transplantation with a readily available family member should be considered as one of the treatment options for patients with refractory acute myeloid leukemia.
Patients and methods

Patients
Between March 1994 and December 1998, 13 consecutive patients with PIF AML were transplanted at our center. Patients had received various combinations of induction chemotherapy prior to referral to our center. Some patients received further cytoreductive chemotherapy at this institution immediately prior to PMRD BMT. Disease status (percentage of blasts in peripheral blood and bone marrow) at the time of transplant was evaluated and recorded.
Donors
Serological typing of HLA in immediate family members was performed. Donor selection was based on disparity of Bone Marrow Transplantation major HLA antigens, gender, age, weight, viral serology, and general health. All donors underwent a complete and detailed history and physical examination.
Clinical protocol
All recipients underwent a detailed pre-BMT evaluation and an Institutional Review Board approved written consent form was obtained before participation in the study. All patients but one received an uniform conditioning regimen, which included total body irradiation (1410 rads), etoposide (20 mg/kg/day × 1), cytarabine (3 g/m 2 every 12 h × six doses), cyclophosphamide (50 mg/kg/day × 2) and highdose steroids around graft infusion time. 6 One patient did not receive anti-thymocyte globulin during the conditioning regimen. Graft-versus-host disease prophylaxis included partial T cell depletion of the graft with anti-CD3 monoclonal antibody (OKT3; Ortho Biotech, Raritan, NJ, USA) Daun = daunorubicin; Ara-C = cytarabine; 6-Thio = 6-thioguanine; Mito = mitoxantrone; Etop = etoposide; CsA = cyclosporine; Ida = idarubicin; Mel = melphalan; PB = peripheral blood; BM = bone marrow; Hypo = hypocellular; Cytored = cytoreduction prior to BMT; t = translocation; tri = trisomy; m = monosomy; NL = normal; Ukn = unknown; multi = multiple chromosomal abnormalities. and complement. In addition, 12 daily doses of ATG (day +5 to +16), steroid, and low-dose cyclosporine were administered post transplant. All patients remained in a private, HEPA-filtered room during transplantation until count recovery. Prophylactic anti-microbial and supportive care measures were given according to standard care guidelines. Pre-emptive donor leukocyte infusion (DLI) for disease relapse was given post BMT in five patients.
Statistics
Patients who received a marrow graft were evaluable for engraftment, GVHD, relapse or death. Engraftment day was defined as the first of 3 consecutive days with WBC equal to or greater than 1 × 10 9 /l. The diagnosis of GVHD was made and graded according to criteria outlined by Glucksberg. 7 Patients who survived beyond 80 days were eligible for evaluation of chronic GVHD. Patients were censored at the date of last follow-up, relapse or death for disease-free survival analysis (Figure 1 ). The probability of relapse and disease-free survival was estimated using the method of Kaplan and Meier. 
Results
Patient and donor characteristics
Patient diagnoses, demographics, cytogenetics, primary induction chemotherapy, and transplant-related therapy are summarized in Table 1 . One patient (UPN 305) with myelodysplastic syndrome had just evolved to AML when he was referred to our center, so there was no prior chemo-therapy given. However, blasts were present in both peripheral blood and bone marrow despite chemotherapy given prior to the transplant. Patient ages ranged from 9 to 59 years (median, 34). Four patients received further chemotherapy to reduce the leukemic burden before BMT. At the time of BMT, the percentage of blasts in bone marrow and peripheral blood ranged from 10% to 73% and 0% to 57%, respectively. The median time from diagnosis to BMT was 5 (range 2-17) months.
Donor characteristics are listed in Table 2 . Donors were family members as follows: children (n = 5), full siblings (n = 4), parents (n = 3), and half-sibling (n = 1). HLA disparities revealed 12 out of 13 donor-recipient pairs were greater than two major HLA antigens mismatched in the GVHD (patient) and rejection (donor) directions, respectively. The contents of CD34 + cells in the infused marrow F  mother  3  2  125  12  M  half brother  2  3  211  38  M  brother  0  2  245  32  F  sister  3  3  246  36  F  mother  2  2  305  31  M  brother  3  1  306  18  M  son  3  3  314  26  F  sister  2  2  321  55  M  father  3  3  418  36  M  son  2  2  421  19  M  son  3  2  471  17  M  son  3  2  483  24  F  daughter  3  3 GVHD = graft-versus-host disease. 
Clinical outcomes
One patient died before engraftment at day +5 due to Klebsiella pneumoniae septicemia. All remaining 12 patients engrafted at a median of day +16 (range: day +12 to +19). Among these 12 evaluable patients, only one developed acute GVHD (grade II), and responded to treatment. Two additional patients died prior to day 100 resulting in a 100-day transplant-related mortality rate of 23%. Ten patients (77%) survived beyond day +100 and were eligible for evaluation of chronic GVHD. Of them, one patient developed extensive chronic GVHD and expired from this condition on day +492 (Table 3) .
Median follow-up of this cohort of patients was 6.5 months. Three patients are alive without disease at 14, 36 and 45 months post BMT, each with a Karnofsky score of 100%. The actuarial 3-year probability of survival was 0.19. The major cause of death was relapse of disease, which occurred in six patients (days +132 to +445) resulting in a probability of relapse of 0.54 at 3 years. Other causes of death included infection (n = 1), pneumonitis (n = 1), adult respiratory distress syndrome (n = 1), and chronic GVHD (n = 1).
Five patients received pre-emptive donor leukocyte infusions to prevent disease relapse. Three of them developed acute GVHD (one of each for grade II, grade III and grade IV) after DLI. Of these five patients, only one (without the development of acute GVHD) is alive; the other four patients all died of relapse (Table 3) .
Discussion
With the advancement of chemotherapeutic regimens, the majority of patients with acute myeloid leukemia will respond to initial induction therapy. However, for those who fail to achieve remission status, the outcome with further chemotherapy is usually dismal. Several studies 4, [9] [10] [11] have addressed the important role of allogeneic bone marrow transplantation for these patients, primarily using matched sibling or matched unrelated donors.
Our experience is unique in that all the donors were mismatched related family members. Developing access to these immediately available donors permits prompt use of bone marrow transplantation, as quickly as 2 months from diagnosis. This short period of time lapse can enable patients to sustain minimal complication from excessive chemotherapy and infection, which results in a better health status prior to transplantation. Thus, and as demonstrated in our experience, the conditioning regimen was well tolerated. Only one patient experienced early death at day +5 due to sudden overwhelming sepsis. All other patients engrafted at a median of day +16 post PMRD BMT. Only one patient developed grade II GVHD and responded to treatment. The engraftment rate, incidence of GVHD, and day 100 transplant-related mortality were comparable with previous reports using matched related or unrelated donors.
We have previously published the observation that an absence of circulating blasts in the peripheral blood was shown to yield a better survival outcome post BMT in children with acute leukemia. 12 There were four patients whose periperal blood blasts counts were between 0% and 5% prior to transplant. Two of these four patients are also longterm survivors. Cytoreductive chemotherapy was administered to four additional patients in this report in various combinations (Ara-C-based or melphalan) with the hope to induce 'peripheral blood remission' prior to BMT. Two of these patients are long-term survivors having achieved a circulating blast count of 0% and 5%, respectively at the time of transplantation. Small numbers preclude further conclusion, but added to the previous 'peripheral blood remission' observation this suggests that further study using a systematic approach with uniform cytoreduction chemotherapy regimen prior to BMT is warranted.
Relapse of leukemia (six out of 13 patients) remains a major cause of death post transplantation. Pre-emptive donor leukocyte infusion was investigated to overcome this obstacle. Five patients without evidence of acute GVHD post BMT received leukocyte infusions from their original bone marrow donor. Three patients developed grade II-IV GVHD post DLI. Only one patient with DLI is a longterm survivor and of interest did not develop GVHD. The remaining four patients who received DLI all died of relapse. The re-introduction of T cells after a T celldepleted bone marrow graft in an HLA-mismatched setting is an intriguing but complicated situation. The appropriate timing and dose is currently under investigation in our institution.
Patients with primary induction failure or refractory acute myeloid leukemia should undergo allogeneic bone marrow transplantation. The results we report here demonstrate that bone marrow transplantation using a readily available partially mismatched related donor can provide durable engraftment and long-term survival comparable to the use of matched sibling or matched unrelated donors. Thus, as time is of the essence upon recognition that a patient with AML is unresponsive to standard-dose chemotherapy, a family donor creates immediate access to transplantation. Since relapse remains the leading cause of failure, further studies should be aimed at novel approaches to leukemia eradication given either prior to or following transplantation.
